期刊
CLINICAL & EXPERIMENTAL METASTASIS
卷 37, 期 2, 页码 247-255出版社
SPRINGER
DOI: 10.1007/s10585-020-10025-3
关键词
Mesenteric lymph duct; Colon cancer; Gastric cancer; Luciferase; Intralymphatic
类别
资金
- Vanderbilt Ingram Cancer Center/Vanderbilt Institute for Infection, Inflammation and Immunology (VI4)
- Office of the Assistant Secretary of Defense for Health Affairs, through the Peer Reviewed Cancer Research Program [W81XWH-18-1-0234]
- NCI/NIH Cancer Center Support Grant [P30 CA068485, S10 OD021804]
- Vanderbilt Mouse Metabolic Phenotyping Center [U24DK059637]
- [T32 CA106183]
Current laboratory models of lymphatic metastasis generally require either genetically modified animals or are technically challenging. Herein, we have developed a robust protocol for the induction of intralymphatic metastasis in wild-type mice with reproducible outcomes. To determine an optimal injection quantity and timeline for tumorigenesis, C57Bl/6 mice were injected directly into the mesenteric lymph duct (MLD) with varying numbers of syngeneic murine colon cancer cells (MC38) or gastric cancer cells (YTN16) expressing GFP/luciferase and monitored over 2-4 weeks. Tumor growth was tracked via whole-animal in vivo bioluminescence imaging (IVIS). Our data indicate that the injection of tumor cells into the MLD is a viable model for lymphatic metastasis as necropsies revealed large tumor burdens and metastasis in regional lymph nodes. This protocol enables a closer study of the role of lymphatics in cancer metastasis and opens a window for the development of novel approaches for treatment of metastatic diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据